German drug maker Merck KGaA (MKGAY.PK) and Pfizer Inc. (PFE) today announced the treatment of the first patient in a Phase III study of avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in an advanced renal cell carcinoma or RCC setting.
from RTT - Biotech http://ift.tt/1PRAvXU
via IFTTT
No comments:
Post a Comment